Published • loading... • Updated
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape
- Harbour BioMed won a U.S. patent infringement case against Amgen involving its antibody discovery technology developed by Professor Frank Grosveld.
- A jury found that Amgen willfully infringed Harbour BioMed's patents and awarded $20,203,704 in damages.
- Harbour BioMed may petition to triple the damages to about $60.6 million due to willful infringement.
- Harbour BioMed plans to enforce additional patents that may involve much higher potential damages in the future.
Insights by Ground AI
44 Articles
44 Articles
The Berkshire Eagle+43 Reposted by 43 other sources
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape
The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platformDelaware jury finds infringement willful and patent valid, and awards full $20.2 million in damages; the…
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources44
Leaning Left7Leaning Right5Center16Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
L 25%
C 57%
R 18%
Factuality
To view factuality data please Upgrade to Premium
